Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
Status:
Completed
Trial end date:
2019-04-25
Target enrollment:
Participant gender:
Summary
Prospective, double-blind, randomized assessment of the efficacy, safety and pharmacokinetic
of Aerucin® as adjunct treatment (in addition to standard of care antibiotics) for pneumonia
caused by P. aeruginosa.